Sunisam 12.5 mg Sunitinib Price USA | Ernest Impex Indian Exporter

Sunisam 12.5 mg Capsule: Precision Multi-Targeted Therapy for Advanced Oncology

Are you searching for a reliable Sunisam 12.5 mg capsule exporter from India? Ernest Impex, a specialized division of the Group of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of advanced tyrosine kinase inhibitors. We operate a high-standard, temperature-monitored supply chain serving Washington (USA), London (UK), Bangkok (Thailand), Canberra (Australia), Singapore, and Kingston (Jamaica), ensuring that critical oncology treatments are delivered with pharmaceutical-grade integrity.

Detailed Product Information: What is Sunisam 12.5 mg?

Sunisam 12.5 mg Capsule is an oral multi-targeted tyrosine kinase inhibitor (TKI) containing the active molecule Sunitinib. Developed by Samarth Life Sciences, a pioneer in specialized pharmaceutical formulations, this 12.5 mg strength is the essential titration dose used in personalized cancer care. It allows oncologists to calibrate the treatment precisely, maximizing the therapeutic window while minimizing dose-dependent toxicity for the patient.

1. Clinical Indications

Sunisam 12.5 mg is a cornerstone treatment for three primary types of cancer:

• Metastatic Renal Cell Carcinoma (mRCC): An advanced treatment for kidney cancer that has progressed.

• Gastrointestinal Stromal Tumor (GIST): Utilized for patients who have shown resistance to Imatinib or are unable to tolerate it.

• Pancreatic Neuroendocrine Tumors (pNET): For progressive, well-differentiated tumors where surgical intervention is not feasible.

2. Mechanism of Action: Cutting Off the Tumor’s Life Support

Sunisam works by simultaneously inhibiting multiple cell surface receptors that cancer cells rely on for survival and expansion:

• Anti-Angiogenesis: It blocks VEGFR (Vascular Endothelial Growth Factor Receptors), which prevents the tumor from growing new blood vessels, effectively "starving" it of nutrients.

• Growth Signal Interruption: It targets PDGFR (Platelet-Derived Growth Factor Receptors) and KIT (Stem Cell Factor Receptor), stopping the internal signals that tell cancer cells to divide rapidly.

• Metastasis Suppression: By blocking these pathways, Sunisam 12.5 mg helps prevent the migration of cancer cells to other parts of the body.

3. Administration and Dosage

• Titration Strategy: The 12.5 mg capsule is frequently used in "step-up" or "step-down" dosing regimens to manage patient-specific side effects.

• Standard Cycle: Often administered in a 6-week cycle (4 weeks on treatment, followed by a 2-week rest period).

• Storage: Store at room temperature (below 30°C) in a dry place, away from direct sunlight.

Why Source Sunisam 12.5 mg from Ernest Impex?

In 2026, pharmaceutical procurement requires supply chain resilience. Ernest Impex provides:

• Direct Sourcing: Genuine inventory from Samarth Life Sciences with 100% batch traceability.

• Global Export Authority: Expert handling of complex documentation for Washington, London, Bangkok, Canberra, Singapore, and Kingston.

• Cold-Chain Integrity: Specialized packaging to ensure the molecular stability of the medication during international transit.

• Regulatory Compliance: Full provision of GMP certificates and batch-specific Certificates of Analysis (COA).